Biotech and pharma companies are betting on a promising class of cancer drugs to drive growthCNBC • 01/14/24
A Bull Market Is Coming: 2 Magnificent Stocks Down More Than 50% to Buy Right NowThe Motley Fool • 01/11/24
Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment CorporationBusiness Wire • 01/10/24
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must WatchSeeking Alpha • 01/10/24